Perjeta Approval History
FDA Approved: Yes (First approved June 8, 2012)
Brand name: Perjeta
Generic name: pertuzumab
Dosage form: Injection
Treatment for: Breast Cancer
Perjeta (pertuzumab) is a humanized monoclonal antibody indicated for the treatment of HER2-positive breast cancer.
Development History and FDA Approval Process for Perjeta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.